To evaluate the efficacy of bemcentinib as add-on therapy to standard of care (SoC) in patients hospitalised with coronavirus disease 2019 (COVID-19)Timepoint: Time to sustained clinical improvement of at least 2 points (from randomisation) on a 9-point category ordinal scale; live discharge from the hospital; or considered fit for discharge (a score of 0; 1; or 2 on the ordinal scale); whichever comes first; by Day 29 (this will also define the â??responderâ?? for the response rate analyses).

To evaluate the efficacy of bemcentinib as add-on therapy to standard of care (SoC) in patients hospitalised with coronavirus disease 2019 (COVID-19)Timepoint: Time to sustained clinical improvement of at least 2 points (from randomisation) on a 9-point category ordinal scale; live discharge from the hospital; or considered fit for discharge (a score of 0; 1; or 2 on the ordinal scale); whichever comes first; by Day 29 (this will also define the â??responderâ?? for the response rate analyses).

N/A

N/A

To evaluate the efficacy of bemcentinib as add-on therapy to standard of care (SoC) in patients hospitalised with coronavirus disease 2019 (COVID-19)Timepoint: Time to sustained clinical improvement of at least 2 points (from randomisation) on a 9-point category ordinal scale; live discharge from the hospital; or considered fit for discharge (a score of 0; 1; or 2 on the ordinal scale); whichever comes first; by Day 29 (this will also define the â??responderâ?? for the response rate analyses).

To evaluate the efficacy of bemcentinib as add-on therapy to standard of care (SoC) in patients hospitalised with coronavirus disease 2019 (COVID-19)Timepoint: Time to sustained clinical improvement of at least 2 points (from randomisation) on a 9-point category ordinal scale; live discharge from the hospital; or considered fit for discharge (a score of 0; 1; or 2 on the ordinal scale); whichever comes first; by Day 29 (this will also define the â??responderâ?? for the response rate analyses).